EcoDrugPlus

Sodium/glucose Cotransporter 1

Ensembl ID : ENSORLG00000009712
Gene Symbol: LOC101175417
4 Cross references
247 Possible Orthologues:

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSORLG00000009679
Gene Symbol: LOC101175176
4 Cross references
247 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSORLG00000002047
Gene Symbol: LOC100049445
3 Cross references
213 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1-Like

Ensembl ID : ENSORLG00000002122
Gene Symbol: LOC101166845
3 Cross references
213 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSORLG00000001837
Gene Symbol: SLC18A2
4 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6, Like

Ensembl ID : ENSORLG00000006079
Gene Symbol: SLC22A6L
4 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSORLG00000004888
Gene Symbol: SLC29A1
4 Cross references
209 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSORLG00000008769
Gene Symbol: SLC5A2
4 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1a

Ensembl ID : ENSORLG00000011608
Gene Symbol: SLC6A1A
4 Cross references
205 Possible Orthologues:

Solute Carrier Family 6 Member 1b

Ensembl ID : ENSORLG00000004595
Gene Symbol: SLC6A1B
4 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSORLG00000013608
Gene Symbol: SLC6A2
4 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSORLG00000005085
Gene Symbol: SLC6A3
4 Cross references
166 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).